Financial Performance - Revenue for the six months ended June 30, 2022, was $404,984 thousand, representing a 5.3% increase from $384,611 thousand in the same period of 2021[10]. - Gross profit for the same period was $247,702 thousand, showing a marginal increase from $247,608 thousand, indicating a stable gross margin[10]. - The company reported a period loss of $(253,275) thousand, compared to $(114,676) thousand in the previous year, reflecting a significant increase in losses[10]. - Loss attributable to equity shareholders was $(198,130) thousand, up from $(90,266) thousand year-over-year[10]. - The company achieved global revenue of $405 million for the six months ending June 30, 2022, representing a year-on-year growth of 10.1%[15]. - The company reported a comprehensive loss of $285,248 thousand for the six months ended June 30, 2022, compared to a loss of $114,676 thousand for the same period in the previous year[146]. - The basic loss per share for the period was 10.94 cents, compared to 5.00 cents in the previous year[136]. - The company reported a net loss attributable to ordinary equity holders of $204,794,000 for the six months ended June 30, 2022, compared to $102,203,000 for the same period in 2021, representing an increase of approximately 100%[174]. Revenue Breakdown - The orthopedic medical device business accounted for 28.6% of total revenue, while the cardiovascular intervention business contributed 15.0%[9]. - The cardiac rhythm management business represented 25.8% of total revenue, indicating strong performance in this segment[9]. - The cardiovascular intervention business saw a significant revenue increase of 28.1% in overseas markets, particularly in the EMEA region and South America, with revenue growth of 62.7% and 48.7% respectively[15]. - The cardiac valve business reported a remarkable revenue growth of 44.8%, with clinical usage and hospital penetration rates both improving[18]. - The orthopedic business experienced a global revenue increase of 2.4%, with international (non-China) revenue growing by 9.7%[15]. - The global cardiac rhythm management business generated approximately $104.4 million in revenue, reflecting a 7.2% year-over-year growth (excluding currency effects)[30]. - The heart valve business generated revenue of approximately $19.0 million, reflecting a year-on-year increase of 44.8% (excluding currency effects), driven by the rapid growth in sales and implant volumes of VitaFlow® and VitaFlow Liberty™[37]. Research and Development - Research and development costs rose by 59.3% to $186.4 million, reflecting increased investment in ongoing and new projects[69]. - The company is actively pursuing market expansion and technological innovation in response to the evolving healthcare landscape in China[23]. - The company emphasizes the importance of independent innovation to establish core competitiveness and international influence in the medical device industry[22]. Market Expansion and Strategy - Future strategies include continuous innovation and expansion into new markets, aiming to enhance patient quality of life through advanced medical solutions[5]. - The company plans to continue focusing on sustainable and high-quality development while providing affordable advanced medical solutions globally[19]. - The company aims to consolidate its leading position in the Chinese medical device market and enhance domestic market share through strong brand recognition and extensive distribution networks[84]. - The company plans to enhance its presence in niche markets such as revision products and smart assistive tools, aiming to provide comprehensive medical solutions for joint diseases[29]. Shareholder Information - As of June 30, 2022, the board members and senior executives held a total of 46,889,899 shares, representing approximately 2.57% of the company's equity[87]. - Major shareholders include Otsuka Holdings Co., Ltd. and Otsuka Medical Devices Co., Ltd., each holding 382,994,120 shares, representing 20.99% of the total issued shares[93]. - The second largest shareholder, the Perfect Foundation, holds 328,363,355 shares, accounting for 18.00% of the total issued shares[93]. Financial Position - Cash and cash equivalents decreased to $1,380.8 million from $1,754.4 million, mainly due to operational expenditures and capital investments[76]. - The total borrowings of the group increased by $65.2 million to $1,090.0 million as of June 30, 2022, compared to $1,024.8 million as of December 31, 2021, resulting in a capital debt ratio rise from 46.2% to 58.4%[78]. - The company reported total assets as of June 30, 2022, were $3.498 billion, a slight decrease from $3.834 billion at the end of 2021[141]. Operational Metrics - The company has established over ten new clinical application and training centers nationwide, providing comprehensive support services to empower grassroots medical institutions[40]. - The company’s international sales team has been established in key markets including the U.S., U.K., Brazil, Japan, and Australia, enhancing its global market strategy[35]. - The company’s innovative products have penetrated 21 overseas markets, including Europe, Latin America, and Southeast Asia[16]. Corporate Governance - The company has established an audit committee in compliance with corporate governance codes, consisting of three members[124]. - The company confirmed compliance with the standards set out in the code of conduct for securities transactions during the six months ended June 30, 2022[100].

| --- | --- | --- | --- | --- | --- | --- | --- | |-------|-------|-------|----------------|-------|-------|-------|--------------------------------------------------------------------------------------------------------| | | | | | | | | | | | | | ØMicroPort微创 | | | | | | | | | 罪度報告 | | | | | | | | | | | | | MicroPort Scientific Corporation 微創醫療科學有限公司 (於開曼群島註冊成立的有限公司) (股票代碼：00853) | Alley Allery Allery All All o 0 0 ti 6 150 | --- | --- | --- | --- | --- | --- | |-------|------------------------------------ ...

ai158746416851_Microport Cover 2019 (c)_12.7mm.pdf 1 21/4/2020 下午6:16 | 目錄 | | --- | | 公司資料 | 3 | | --- | --- | | 財務摘要 | 4 | | 五年財務摘要 | 5 | | 公司概況 | 6 | | 主席報告 | 7 | | 管理層討論及分析 | 10 | | 董事會及高級管理層 | 28 | | 董事會報告 | 33 | | 企業管治報告 | 50 | | 環境、社會及管治報告 | 66 | | 獨立核數師報告 | 97 | | 綜合損益表 | 104 | | 綜合損益及其他全面收益表 | 105 | | 綜合財務狀況表 | 106 | | 綜合權益變動表 | 108 | | 綜合現金流量表 | 110 | | 財務報表附註 | 112 | 1 微創醫療科學有限公司 2019年度報告 2 微創醫療科學有限公司 2019年度報告 公司資料 董事 執行董事 常兆華博士 （董事會主席兼首席執行官） 非執行董事 蘆田典裕先生 白藤泰司先生 余洪亮先生 獨立非執行董事 周嘉鴻先生 劉國恩博士 邵春陽先生 公司 ...